Ana Giménez-Capitán

Suggest Changes
Learn More
PURPOSE Concomitant genetic alterations could account for transient clinical responses to tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR mutations. (More)